Abstract 937P
Background
Pain, fatigue and depression are commonly seen in cancer survivors and may co-occur. The extent of these symptoms occurring, alone or together, in head and neck cancer (HNC) is unknown. Using data from the Head and Neck 5000 cohort, we (i) investigated prevalence of the pain, fatigue, depression symptom cluster and (ii) explored its association with health-related quality of life (HRQoL).
Methods
Sociodemographic and clinical data were collected from participants at cohort recruitment (pre-treatment). At 12-months post-recruitment, cancer-related pain, fatigue and HRQoL were measured using the EORTC QLQ-C30, and depression using the Hospital Anxiety & Depression Scale (HADS). Cut-offs to define presence of clinically-important symptoms were: pain ≥25, fatigue ≥39 and depression ≥8. Associations between HRQoL score (on scale 1-100; higher score=better HRQoL) and the symptom cluster (0/1/2/3 symptoms), adjusted for clinical and sociodemographic variables, were assessed using multivariate linear regression.
Results
2,207 patients were included in the analysis. 47.3% had one or more symptoms of pain, fatigue or depression at clinically important levels. 20.3% had any one symptom, 13.7% had any two symptoms and 13.4% had all three symptoms. In the multivariate analysis, number of symptoms was strongly associated with HRQoL. After adjusting for other variables, presence of any one symptom was associated with a 13.4 point decrease (95% CI -15.2 to -11.7) in HRQoL, any two symptoms with a 26.3 point decrease (95% CI -28.3 to -24.3) and all three symptoms with a 42.3 point decrease (95% CI -44.3 to -40.2) in the HRQoL.
Conclusions
There is a high prevalence of the pain, fatigue and depression cluster in HNC survivors with over one in ten experiencing all three symptoms at 12-months. They have a significant negative impact on HRQoL. More attention should be given to identifying survivors experiencing this symptom cluster. Interventions targeted at addressing the cluster symptoms may help improve HRQoL amongst HNC survivors.
Clinical trial identification
N/A
Editorial acknowledgement
Funding
National Institute for Health and Care Research (NIHR).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
917P - Automatic characterization of spatial arrangement of tumor-infiltrating lymphocytes identifies oral cavity squamous cell carcinoma patients with poorer prognosis
Presenter: German Corredor
Session: Poster session 03
918P - Deciphering the molecular drivers behind locoregional progression, intratumoral heterogeneity, and clonal evolution in locally advanced head and neck cancer
Presenter: Gema Bruixola
Session: Poster session 03
919P - Predictive multi-omic signature in locally advanced laryngeal/hypopharyngeal (LH) squamous cell carcinoma (SCC) treated with induction chemotherapy (IC)
Presenter: Paolo Bossi
Session: Poster session 03
920P - Genomic landscape of head and neck cancer in Asia: A comprehensive meta-analysis of 1016 samples
Presenter: Sewanti Limaye
Session: Poster session 03
Resources:
Abstract
921P - Divergent fates: The ambiguous role of M2-like TAMs in oropharyngeal cancer
Presenter: Michael Saerens
Session: Poster session 03
922P - Genomic instability as a biomarker for advanced cancer of the head and neck
Presenter: Filippo Dall'Olio
Session: Poster session 03
923P - Tumor-informed ctDNA assay to predict recurrence in locally advanced SCCHN
Presenter: Natasha Honoré
Session: Poster session 03
924P - Claudin-1 (CLDN1) tight junction protein expression delineates distinct immune infiltrates in ascending (A) vs descending (D) subtypes of nasopharyngeal carcinoma: Potential implications for treatment selection
Presenter: Darren Wan-Teck Lim
Session: Poster session 03
925P - External validation of the CD8 radiomics signature as a prognostic marker in recurrent or metastatic head and neck cancer treated with nivolumab
Presenter: Laville Adrien
Session: Poster session 03
926P - Genetic alteration in olfactory neuroblastoma: Unraveling carcinogenesis mechanisms and chemotherapy resistance through whole exome sequencing analysis
Presenter: Haruhi Furukawa
Session: Poster session 03